Zhang Lihua, Desai Nihar R, Li Jing, Hu Shuang, Wang Qing, Li Xi, Masoudi Frederick A, Spertus John A, Nuti Sudhakar V, Wang Sisi, Krumholz Harlan M, Jiang Lixin
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (L.Z., J.L., S.H., Q.W., X.L., L.J.).
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (N.R.D., S.V.N., S.W., H.M.K.) Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (N.R.D., H.M.K.).
J Am Heart Assoc. 2015 Jul 10;4(7):e001906. doi: 10.1161/JAHA.115.001906.
Early clopidogrel administration to patients with acute myocardial infarction (AMI) has been demonstrated to improve outcomes in a large Chinese trial. However, patterns of use of clopidogrel for patients with AMI in China are unknown.
From a nationally representative sample of AMI patients from 2006 and 2011, we identified 11 944 eligible patients for clopidogrel therapy and measured early clopidogrel use, defined as initiation within 24 hours of hospital admission. Among the patients eligible for clopidogrel, the weighted rate of early clopidogrel therapy increased from 45.7% in 2006 to 79.8% in 2011 (P<0.001). In 2006 and 2011, there was significant variation in early clopidogrel use by region, ranging from 1.5% to 58.0% in 2006 (P<0.001) and 48.7% to 87.7% in 2011 (P<0.001). While early use of clopidogrel was uniformly high in urban hospitals in 2011 (median 89.3%; interquartile range: 80.1% to 94.5%), there was marked heterogeneity among rural hospitals (median 50.0%; interquartile range: 11.5% to 84.4%). Patients without reperfusion therapy and those admitted to rural hospitals were less likely to be treated with clopidogrel.
Although the use of early clopidogrel therapy in patients with AMI has increased substantially in China, there is notable wide variation across hospitals, with much less adoption in rural hospitals. Quality improvement initiatives are needed to increase consistency of early clopidogrel use for patients with AMI.
URL: https://www.clinicaltrials.gov/. Unique identifier: NCT01624883.
在中国的一项大型试验中,已证明对急性心肌梗死(AMI)患者早期给予氯吡格雷可改善预后。然而,中国AMI患者使用氯吡格雷的模式尚不清楚。
从2006年和2011年全国代表性的AMI患者样本中,我们确定了11944例符合氯吡格雷治疗条件的患者,并测量了早期氯吡格雷的使用情况,定义为在入院24小时内开始用药。在符合氯吡格雷治疗条件的患者中,早期氯吡格雷治疗的加权率从2006年的45.7%增至2011年的79.8%(P<0.001)。2006年和2011年,各地区早期氯吡格雷的使用存在显著差异,2006年为1.5%至58.0%(P<0.001),2011年为48.7%至87.7%(P<0.001)。虽然2011年城市医院早期使用氯吡格雷的比例普遍较高(中位数89.3%;四分位间距:80.1%至94.5%),但农村医院之间存在明显异质性(中位数50.0%;四分位间距:11.5%至84.4%)。未接受再灌注治疗的患者以及入住农村医院的患者接受氯吡格雷治疗的可能性较小。
尽管中国AMI患者早期使用氯吡格雷治疗的情况有了大幅增加,但各医院之间仍存在显著差异,农村医院的采用率要低得多。需要开展质量改进举措,以提高AMI患者早期使用氯吡格雷的一致性。